De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?

Lorini, L ; Gili, R ; et al.

In: Oral oncology, Jg. 152 (2024-05-01), S. 106768

Online academicJournal

Zugriff:

Zum Volltext

De novo metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) constitutes 10% of recurrent/metastatic (RM) cases. Radiotherapy (RT) has a crucial role in the treatment of locally advanced HNSCC, however its application on RM diseases is still limited. The advent of immune checkpoint inhibitors (ICIs) improves the survival of RM HNSCC, however median overall survival is still limited. Integration of locoregional RT with ICIs in de novo metastatic HNSCC represents a promising treatment option. This perspective aims to explore the role of the combination of locoregional and systemic treatment in improving outcomes for synchronous de novo metastatic HNSCC patients and highlights the principal crucial point in decision making.

Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Titel:	De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
Autor/in / Beteiligte Person:	Lorini, L ; Gili, R ; Salvestrini, V ; Morelli, I ; Smussi, D ; Petrelli, F ; Bonomo, P ; Bossi, P
Link:	Zum Volltext
Zeitschrift:	Oral oncology, Jg. 152 (2024-05-01), S. 106768
Veröffentlichung:	Amsterdam : Elsevier ; <i>Original Publication</i>: Oxford ; New York : Pergamon, c1997-, 2024
Medientyp:	academicJournal
ISSN:	1879-0593 (electronic)
DOI:	10.1016/j.oraloncology.2024.106768
Schlagwort:	Humans Neoplasm Metastasis Immune Checkpoint Inhibitors therapeutic use Neoplasm Recurrence, Local Squamous Cell Carcinoma of Head and Neck therapy Squamous Cell Carcinoma of Head and Neck secondary Squamous Cell Carcinoma of Head and Neck radiotherapy Squamous Cell Carcinoma of Head and Neck mortality Squamous Cell Carcinoma of Head and Neck pathology Head and Neck Neoplasms pathology Head and Neck Neoplasms therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Review Language: English [Oral Oncol] 2024 May; Vol. 152, pp. 106768. <i>Date of Electronic Publication: </i>2024 Mar 28. MeSH Terms: Squamous Cell Carcinoma of Head and Neck* / therapy ; Squamous Cell Carcinoma of Head and Neck* / secondary ; Squamous Cell Carcinoma of Head and Neck* / radiotherapy ; Squamous Cell Carcinoma of Head and Neck* / mortality ; Squamous Cell Carcinoma of Head and Neck* / pathology ; Head and Neck Neoplasms* / pathology ; Head and Neck Neoplasms* / therapy ; Humans ; Neoplasm Metastasis ; Immune Checkpoint Inhibitors / therapeutic use ; Neoplasm Recurrence, Local Contributed Indexing: Keywords: De novo metastatic head and neck squamous cell carcinoma; Immunotherapy; Quality of Life; Radiation Substance Nomenclature: 0 (Immune Checkpoint Inhibitors) Entry Date(s): Date Created: 20240329 Date Completed: 20240430 Latest Revision: 20240531 Update Code: 20240531

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.